Rx Rebates To Foreign Governments Could Blunt Reimportation
Executive Summary
Drug manufacturers' recent pricing actions overseas may signal a new strategy to counter proposals for reimporting drugs into the U.S., American Enterprise Institute fellow Scott Gottlieb, MD, suggested Nov. 9
You may also be interested in...
GOP Victory Won’t End Rx Import Debate: New Senators Want Open Borders
Seven of the nine new Senators who will join the chamber in January have professed their support for importing prescription drugs into the U.S
CMS’ Gottlieb returns to AEI
Centers for Medicare & Medicaid Services Senior Advisor for Medical Technology Scott Gottlieb, MD, is leaving the agency for the American Enterprise Institute. Gottlieb is returning to AEI to serve as a fellow after serving as an advisor to Mark McClellan both at FDA, where McClellan was commissioner from November 2002 to February 2004, and CMS, where McClellan is administrator (1"The Pink Sheet" May 10, 2004, p. 32)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011